Pharmacometric methodologies and their use for lenalidomide drug development in chronic lymphocytic leukaemia /
Files
(Published version)
Date
2019
Authors
Hughes, Jim Henry
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
thesis
Citation
Statement of Responsibility
Conference Name
Abstract
Chronic lymphocytic leukaemia is a haematological cancer that is characterised by eventual relapse after treatment with no guaranteed cure available. The use of lenalidomide in this cancer has been trialled with little success due to high toxicity. Optimisation of lenalidomide therapy is unlikely to occur without determining the reasons behind this toxicity. This thesis aimed to explore the pharmacokinetics of lenalidomide and methodologies that could benefit future clinical studies, including ones investigating lenalidomide pharmacodynamics.
School/Discipline
University of South Australia. School of Pharmacy and Medical Sciences.
School of Pharmacy and Medical Sciences.
School of Pharmacy and Medical Sciences.
Dissertation Note
Thesis (PhD(Pharmacology))--University of South Australia, 2019.
Provenance
Copyright 2019 Jim Henry Hughes.
Description
1 ethesis (xii, 184 pages) :
illustrations (some colour), charts (some colour).
Includes bibliographical references (pages 156-170)
illustrations (some colour), charts (some colour).
Includes bibliographical references (pages 156-170)
Access Status
506 0#$fstar $2Unrestricted online access